Oncimmune® (USA) Reports a Rise in Interest Surrounding EarlyCDT®-Lung as Many Resolve to Quit Smoking in 2012

Share Article

Oncimmune® (USA) LLC, creator of a commercially available blood test designed to aid physicians in the risk assessment and early detection of lung cancer, experiences a rise in online traffic as people worldwide set New Year’s resolutions to quit smoking. The 5th most common New Year’s resolution, those striving to quit smoking are turning to the internet to learn about the risks associated with the habit; a trend which is driving increased traffic to the company’s educational website, http://www.hellohaveyouheard.com.

Finding lung cancer at its earliest stages
We truly hope that it will help to inspire those attempting to quit smoking in the New Year to stay the course.

Oncimmune® (USA) LLC, creator of EarlyCDT®-Lung, a simple blood test that aids physicians in the risk assessment and early detection of lung cancer, is experiencing an increase in web traffic as many people across the country set New Year’s resolutions to quit smoking.

Founded in 2006, Oncimmune (USA) LLC is a leader in the field of cancer detection research, working to develop effective early lung cancer detection methods. Now offering EarlyCDT-Lung in all 50 states, Oncimmune is helping physicians change their approach to lung cancer detection. EarlyCDT-Lung is a simple blood test that measures specific autoantibodies, or immuno-biomarkers, which are elevated in patients with lung cancer. Because these autoantibodies are present at the earliest stages of lung cancer, EarlyCDT-Lung can aid in the diagnosis of lung cancer even before a patient exhibits specific symptoms of the disease.

According to a recent report from the Centers for Disease Control (CDC), smoking is the largest cause of preventable death in the United States, totaling a staggering 443,000 deaths each year. In addition, health-care costs and lost productivity which can be attributed to smoking related deaths add up to a $193 billion strain on the U.S. economy annually. Continued efforts by government agencies, including the CDC and private companies such as Oncimmune, have helped to foster conversation surrounding the dangers of smoking and the importance of early lung cancer detection.

It’s no surprise that giving up smoking is one of the most common New Year’s resolutions made annually. In fact, many reports rank it as the fifth most common resolution people make, but are not able to sustain long-term cessation. In hopes to provide support and encouragement to those attempting the kick the habit in 2012, the Oncimmune team released a series of “Top 10” blog posts and an accompanying newsletter. The series entitled “Your Health in 2012” addresses the many dangers of smoking and the importance of quitting the habit. Hosted on Oncimunne’s blog, at HelloHaveYouHeard.com, the eye opening posts include:

“Top 10 Lung Cancer Symptoms,” posted on January 5, received over 500 visits, ranking it among the site’s most visited pages. These numbers speak directly to a rising public awareness around the dangers of lung cancer and a renewed interest in early detection.

“We are pleasantly surprised at the response we received from our latest blog and newsletter series,” said Greg Stanley, Chief Commercial Officer, of Oncimmune. “We truly hope that it will help to inspire those attempting to quit smoking in the New Year to stay the course.”

Oncimmune is committed to an on-going public education effort surrounding lung cancer risk and the importance of preventative and early detection tools. Recent efforts have included: an educational video series, the launch of the Lung Cancer Awareness Wall, and a blog series featuring 30 unique stories of individuals who have been affected by lung cancer. Watch for more educational initiatives from the Oncimmune team in the coming months, as they explore new and innovative ways to inspire conversation about the importance of early lung cancer detection.

About Oncimmune (USA) LLC

Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. The company is committed to advancing early cancer detection through proprietary immuno-biomarker technologies based on biological technology identified by John Robertson, M.D., Professor of Surgery at Nottingham University, England, and Chief Scientific Officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Professor Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90% of solid-tumor cancers, which make up 70% of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. All testing is performed exclusively at Oncimmune’s CLIA (Clinical Laboratory Improvement Act) regulated laboratory located in the metro Kansas City area. Oncimmune (USA) LLC is a wholly owned subsidiary of Oncimmune LTD. Oncimmune LTD owns a portfolio of patents, including Patent Nos. 7,402,403 and 7,205,117, with five others currently filed and under review. For more information about Oncimmune, visit: http://www.hellohaveyouheard.com.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Greg Stanley
Visit website